MTHFR Heterozygous vs Homozygous: What Each Means in Practice
By Izel · Genetics & Bioengineering · 10+ years · Genova Lab
Summary
MTHFR genotypes are reported as CC (normal/reference), CT (heterozygous, one variant copy), or TT (homozygous, two variant copies). CT heterozygous status reduces MTHFR enzyme activity by approximately 35% and is clinically modest in most healthy adults with adequate dietary folate. TT homozygous status reduces enzyme activity by approximately 70% and shows the strongest and most consistent research associations with elevated homocysteine. CT heterozygotes generally do not require methylfolate supplementation unless homocysteine is elevated or they are compound heterozygous with A1298C. TT homozygotes should measure baseline homocysteine before considering methylfolate, with COMT genotype determining appropriate dose escalation strategy.
Key points
- CC = normal MTHFR enzyme activity, no intervention needed
- CT = heterozygous, ~35% activity reduction, usually clinically modest
- TT = homozygous, ~70% activity reduction, strongest research associations
- Compound heterozygous (one C677T + one A1298C) is functionally distinct from either alone
- Baseline homocysteine measurement is the highest-leverage diagnostic step for any genotype
When you get your MTHFR C677T result from 23andMe, AncestryDNA, or any other consumer genetics test, the result comes back as one of three genotypes: CC (normal), CT (heterozygous), or TT (homozygous). The clinical and functional differences between these three are larger than most popular content acknowledges — and understanding them is the foundation of any meaningful intervention decision.
The basic biology
You inherit one copy of each gene from each parent. For any single nucleotide polymorphism (SNP), each copy can carry either the reference allele or the variant allele. For MTHFR C677T (rs1801133):
CC (normal): Both copies carry the reference allele. Enzyme function is at full activity. No methylation impairment from this variant.
CT (heterozygous): One reference, one variant. Approximately 35% reduction in enzyme activity. Clinically modest impact in most healthy adults with adequate dietary folate.
TT (homozygous): Both copies carry the variant. Approximately 70% reduction in enzyme activity. This is the genotype most associated with elevated homocysteine and the most likely to benefit from targeted methylfolate supplementation.
Why heterozygous matters less than people think
A 35% reduction in enzyme activity sounds significant. In practice, for a heterozygous CT carrier eating a varied diet with adequate folate intake, the functional consequence is usually modest. Most CT heterozygotes have homocysteine levels within the normal range, and the cardiovascular and neurological risk markers associated with TT homozygosity show much weaker associations in CT individuals.
The functional medicine community has occasionally treated CT heterozygosity as a major clinical finding requiring aggressive intervention. The research does not support that framing. CT heterozygotes generally do not need high-dose methylfolate supplementation. They do benefit from ensuring adequate dietary folate (leafy greens, legumes, pulses) and adequate riboflavin (B2), which is the cofactor MTHFR requires to function.
The exceptions: CT heterozygotes who are also A1298C carriers (compound heterozygous), those with documented elevated homocysteine, pregnant women (where neural tube defect risk is the relevant consideration), and those with significant nutritional deficiencies or absorption issues.
Why homozygous matters more
TT homozygosity is where the most consistent clinical research findings cluster. Roughly 70% reduced enzyme activity means folate conversion is significantly impaired, and downstream methylation capacity is constrained. The most robust association is with elevated plasma homocysteine — particularly in populations with low dietary folate intake.
For TT homozygotes, measuring baseline homocysteine is the highest-leverage diagnostic step before any supplementation decision. If homocysteine is elevated (above approximately 9 μmol/L), methylfolate supplementation with riboflavin and methylcobalamin (or hydroxocobalamin) cofactors is a reasonable starting framework. If homocysteine is normal despite TT genotype, the variant may be compensated through dietary intake and other pathways, and aggressive supplementation is unlikely to add value and may cause side effects.
The COMT dimension
A point most MTHFR content misses entirely: your response to methylfolate supplementation depends substantially on your COMT genotype. COMT (catechol-O-methyltransferase) clears catecholamines using methyl groups from the same SAM pool that methylation depends on.
If you are a TT homozygous MTHFR carrier and a COMT Met/Met carrier (slow catecholamine clearance), high-dose methylfolate can drive symptoms of anxiety, irritability, and overstimulation by increasing methyl group availability for COMT-mediated neurotransmitter breakdown faster than your system can handle. This interaction is documented and is one of the most common causes of "methylfolate intolerance" reported in DIY supplementation contexts.
If you are TT MTHFR and Val/Val COMT (fast clearance), methylfolate is usually well tolerated and the standard dose range applies.
Practical implications by genotype
CC (normal): No specific MTHFR intervention required. Standard nutritional folate intake is sufficient.
CT (heterozygous): Ensure adequate dietary folate and riboflavin. Measure homocysteine if mood, cardiovascular, or fertility concerns. Methylfolate supplementation typically not needed unless homocysteine is elevated or compound heterozygous with A1298C.
TT (homozygous): Measure baseline homocysteine. If elevated, methylfolate (400–800 mcg) with riboflavin and methylcobalamin is a starting framework. COMT genotype determines dose escalation strategy. CBS status should also be considered for sulfur pathway downstream complications.